Table 2 Currently recruiting clinical trials targeting CD47 in hematological malignancies
NCT | Phase | Malignancy type | Agent used | Target |
|---|---|---|---|---|
NCT02953509 | 1&2 | NHL | Hu5F9-G4+Rituximab | CD47 + CD20 |
NCT03527147 | 1 | NHL | Hu5F9-G4+Rituximab | CD47 + CD20 |
NCT03248479 | 1 | AML-MDS | Hu5F9-G4+Azacitidine | CD47 + DNA methyltransferase |
NCT02367196 | 1 | H. Neoplasm | CC90002+Rituximab | CD47 + CD20 |
NCT02663518 | 1 | H. Neoplasm | TTI-621+Rituximab | CD47 + CD20 |
NCT02890368 | 1 | Mycosis Fungoides | TTI-621+Anti PD-L1 | CD47 + PD-L1 |
NCT03530683 | 1 | MM | TTI-622+Carfilzomib | CD47+ 26S proteasome |
NCT03013218 | 1 | NHL | ALX148+ Rituximab | CD47 + CD20 |
NCT03512340 | 1 | H. Neoplasm | SRF231 | CD47 |
NCT03763149 | 1 | Lymphoma | IBI188 | CD47 |
NCT03717103 | 1 | NHL | IBI188 + Rituximab | CD47+ CD20 |